What is TPST's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TPST?

P/E (TTM) is n/a and 52-week range is $0.74 to $12.23 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TPST figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TPST?

The company profile lists revenue (TTM) near $30M, net income (TTM) near $-292.43B, EPS (TTM) near $-4.49 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tempest Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Brisbane California, California, US, 16M shares outstanding, ISIN US87978U2078 when available from company profile and filing metadata.

Tempest Therapeutics Inc

$TPST

Health Care · Biotechnology

IR Run Scenarios

$0.76

-1.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 4 full-time employees. The company went IPO on 2012-10-04. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Employees

Website

www.tempesttx.com/

IPO

2012-10-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)